Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-04-30

Study Completion Date

2006-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

NCT00010049

Brain and Central Nervous System Tumors

COMPLETED PHASE1/PHASE2

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

NCT00049127

Adult Anaplastic Oligodendroglioma Adult Mixed Glioma Adult Oligodendroglioma +1 more

COMPLETED PHASE1/PHASE2

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

NCT00045734

Adult Grade I Meningioma Adult Grade II Meningioma Adult Grade III Meningioma +3 more

COMPLETED PHASE2

Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

NCT00401024

Brain and Central Nervous System Tumors

COMPLETED PHASE1

Imatinib Mesylate in Treating Patients With Gliomas

NCT00039364

Brain and Central Nervous System Tumors

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

imatinib mesylate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically documented diagnosis of GBM.
2. Immunohistochemical documentation of expression of PDGFR.
3. Unresectable, recurrent disease by MRI and spectroscopy

Exclusion Criteria

1. Treatment with any other investigational agents within 28 days of first day of study drug dosing.
2. Concurrent chemotherapy.
3. Concurrent radiotherapy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No